Objective-High-density lipoprotein (HDL) from nondiabetic patients with metabolic syndrome (MetS) displays abnormalities in their lipidome, such as triglyceride enrichment and sphingosine-1-phosphate depletion. We hypothesized that these abnormalities could impair the ability of HDL to stimulate endothelial nitric oxide synthase (eNOS). Approach and Results-Compared with HDL from control subjects, HDL from normoglycemic patients with MetS was 39% richer in triglycerides (P<0.01) and 15% poorer in sphingosine-1-phosphate (P<0.05; n=23 in each group). eNOS activity, assessed by the conversion of L-[
T he risk of cardiovascular disease is greater in patients with insulin resistance and metabolic syndrome (MetS), with or without diabetes mellitus, than in subjects without MetS, and cardiovascular diseases are the major cause of morbidity and mortality in these patients. [1] [2] [3] The increased development of atherosclerotic lesions in MetS is multifactorial, but dyslipidemia, characterized by quantitative and qualitative abnormalities of apolipoprotein (apo) B-containing lipoproteins and of high-density lipoproteins (HDL), plays a major role.
The concentration of HDL particles is decreased in MetS. Moreover, they are triglyceride (TG) enriched, and we recently demonstrated abnormalities of their sphingophospholipidome, with, in particular, a decrease in sphingosine-1-phosphate (S1P). [4] [5] [6] These abnormalities are observed at an early stage of MetS, before the appearance of hyperglycemia. They are likely to impair the functionality of HDL and, thus, their antiatherogenic properties. Besides promoting cholesterol efflux, HDL possesses key cardiovascular protective functions, including stimulation of the production of nitric oxide (NO) by endothelial cells. 7 NO exerts strong antiatherogenic effects by the nitrosylation of proteins, which induces vasodilatation and the inhibition of different factors that promote atherosclerosis progression. 8 Endothelial dysfunction, especially reduced NO bioavailability, is considered to play a major role in the initiation and progression of atherosclerosis. 9 HDL activates endothelial NO synthase (eNOS) by binding to scavenger receptor class B type I, with apoA-I as the main ligand, and to S1P receptors, which in turn activates an Akt (protein kinase B)-dependent pathway, inducing the eNOS phosphorylation at serine 1177 (Ser1177). [10] [11] [12] [13] In vitro studies have shown that HDL-bound S1P is crucial for eNOS activation induced by HDL because the deletion of S1P receptors suppresses 60% of eNOS activation. 10 As far as the TG enrichment of HDL is concerned, it reduces the exposure of apoA-I to the aqueous phase and impairs the antioxidant activity of HDL. 14, 15 Thus, it may also impair the binding of apoA-I to scavenger receptor class B type I and the activation of eNOS.
While the ability of HDL from patients with type 2 diabetes mellitus to induce NO synthesis by endothelial cells has been demonstrated to be decreased, that of patients with MetS but normal glycemia remains unknown to date. 16 Qualitative abnormalities such as TG enrichment and S1P depletion are likely to impair the ability of HDL from these patients to activate eNOS. The aim of this work was first to investigate whether the induction of NO synthesis is impaired in MetS patients and then to determine whether TG enrichment or S1P depletion are responsible for the impaired eNOS activity.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Characteristics of the Population
Clinical and biochemical characteristics of controls and nondiabetic MetS patients are given in Table 1 . The nondiabetic MetS patients were all abdominally obese (129±8 and 120±5 cm of waist circumference for females and males, respectively), with a mean body mass index of 41.5±6.1 kg/m 2 . By contrast, all control subjects had a body mass index <28 kg/ m 2 (P=0.0003). Hypertension was found in 14 (60%) MetS subjects, including 3 with antihypertensive drugs. As a result of inclusion criteria, all control or MetS subjects displayed normal fasting glycemia (ie, ≤6.1 mmol/L), which was comparable between the 2 groups (P=0.39). The lipid panel in nondiabetic MetS patients exhibited typical features of MetS, with levels of serum TG 90% higher (P<0.0001) and levels of HDL cholesterol 33% lower (P<0.0001) than those found in control subjects. Fifty-seven percent of MetS patients had triglyceridemia >1.7 mmol/L, 65% had HDL cholesterolemia <1.03 mmol/L for males or <1.29 mmol/L for females, respectively, and 35% displayed both criteria.
HDL Composition and S1P Content
The TG/apoA-I ratio was 39% higher in HDL isolated from nondiabetic MetS patients than in HDL from control subjects (P=0.0012), whereas the esterified cholesterol/apoA-I ratio was 24% lower (P=0.0002; Table 2 ). The proportion of apoA-I among total HDL proteins was similar in MetS and control groups (76.1±5.5% versus 82.7±12.4%; P=0.070). The concentration of S1P in the HDL fraction standardized by the concentration of HDL-apoA-I was significantly lower, by 14.2%, in the MetS group (281±56 versus 327±81 nmol/g apoA-I; P=0.045). A decrease of 16.4% was also found when the concentration of HDL-S1P was standardized by the concentration of HDL proteins (214±45 versus 255±81 nmol/g proteins; P=0.036). The apoM/apoA-I mass ratio in HDL fractions was similar in MetS and control groups (2.68±0.69% versus 2.37±1.11%; P=0.23). The S1P/apoM molar ratio was 30% lower in HDL from MetS patients than in HDL from controls (24.5±7.5 versus 35.1±13.6%; P=0.0043). 119±57% increase in eNOS activity relative to unstimulated cells, that is, incubated without HDL (P<0.0001; Figure 1 ). HDL from nondiabetic MetS patients failed to stimulate eNOS activity to the same extent, exhibiting a 69% reduction in HDL-induced eNOS activity (37±54% versus 119±57%; P<0.0001). Interestingly, HDL-induced eNOS activity correlated significantly in the whole population with the TG/apoA-I ratio (r=−0.354; P=0.017) and the S1P/apoA-I ratio in HDL fraction (r=0.332; P=0.026; Table 3 ).
HDL-Induced eNOS Activity Is Impaired in Nondiabetic MetS Patients
HDL-Induced eNOS Activation by Phosphorylation at Ser1177 Is Reduced in Nondiabetic MetS Patients
The level of Ser1177-phospho-eNOS increased by 45.4±14.7% when HUVECs were incubated with HDL from control subjects relative to unstimulated cells (P<0.0001; Figure 2A ). But, when HUVECs were incubated with HDL from nondiabetic MetS patients, the stimulation was 37% smaller than with HDL from control subjects (28.5±9.8% versus 45.4±14.7%; P=0.0003). In parallel with the decrease in Ser1177-phospho-eNOS, we observed a 39% reduction in the level of Ser473-phospho-Akt with HDL from nondiabetic MetS patients in comparison with HDL from control subjects (52±42% versus 85±50%; P=0.042; Figure 2B ).
The level of Thr495-phospho-eNOS in HUVEC, measured by flow cytometry, was not significantly different by incubating HDL from controls or from MetS subjects (−5±28% versus 5±38%; P=0.18; Figure 2C ).
The HDL-induced eNOS phosphorylation at Ser1177 correlated with the HDL-induced eNOS activity in the whole studied population (r=0.514; P=0.0003; Table 3 ). The HDLinduced eNOS phosphorylation at Ser1177 also correlated with the TG/apoA-I ratio (r=−0.309; P=0.036) and with the S1P/apoA-I ratio (r=0.517; P=0.0002).
S1P Receptor 1 Mediates HDL Effects on eNOS-Activating Pathway
Previous works reported that HUVEC express S1P1 and S1P3, but do not express S1P2, S1P4, or S1P5. 17, 18 To determine which S1P receptor/s are involved in the stimulation of HDL-induced eNOS signaling pathway in HUVEC, we followed a pharmacological approach using S1P1-(ie, W146) and S1P3-(ie, CAY10444) specific antagonists and HDL particles from normolipemic control subjects. Results are shown in Figure I in the Ratios are presented as mass ratios (except for the S1P/apoA-I and S1P/ proteins ratios). CE indicates cholesteryl ester; FC, free cholesterol; MetS, metabolic syndrome; PC, phosphatidylcholines; S1P, sphingosine-1-phosphate; and TG, triglycerides. online-only Data Supplement. Blockage of S1P1 with W146 significantly decreased the levels of Ser1177-phospho-eNOS (from 285±50% to 170±42%; P=0.034) and Ser473-phosphoAkt (from 91±45% to 0±11%; P=0.032). On the contrary, blockage of S1P3 with CAY10444 had no significant effect on the HDL-induced phosphorylation of eNOS (from 285±50% to 248±60%; P=0.50) and Akt (from 91±45% to 62±40%; P=0.23).
S1P Enrichment of HDL From Nondiabetic MetS Patients Promotes Restoration of eNOS Activation
To evaluate the role of S1P depletion in the impaired ability of HDL to activate eNOS in nondiabetic MetS patients, we enriched S1P-depleted HDL with external S1P and subsequently determined whether the functionality of HDL was restored. For this purpose, HDL fractions from 3 nondiabetic MetS patients and from 3 control subjects were selected because of an HDL-S1P level representative of their respective whole group and were subsequently loaded with purified S1P. Thus, MetS HDL were enriched with S1P to a physiological level of +33.0±2.4% (from 260±24 nmol/g apoA-I in native MetS HDL to 346±26 nmol/g apoA-I in S1P-loaded MetS HDL; Figure 3A) . The stimulation of eNOS activity in HUVEC was more efficient during incubation with S1P-loaded HDL than with the corresponding native HDL (from 35±29% to 145±46%; P=0.036; Figure 3B ). The S1P/apoA-I ratio obtained after enrichment was similar to that of HDL from the whole control group (346±26 versus 327±81 nmol/g apoA-I), and S1P enrichment totally normalized eNOS activity (145±46% versus 119±57% with HDL from the whole control group).
In addition, we also evaluated the impact of S1P loading on eNOS phosphorylation. Because of the unavailability of reagents from the manufacturer, it was not possible to quantify Ser1177-phospho-eNOS by flow cytometry, as we had done up to that point. Therefore, Ser1177-phospho-eNOS and Figure 2 . Effects of high-density lipoprotein (HDL) from control and nondiabetic metabolic syndrome (MetS) subjects on endothelial nitric oxide synthase (eNOS)-activating phosphorylation at Ser1177 (A), Akt (protein kinase B)-activating phosphorylation at Ser473 (B), and on eNOSinhibiting phosphorylation at Thr495 (C). Human umbilical vein endothelial cells (HUVEC) were incubated for 5 minutes with HDL (800 μg/mL). The amount of Ser1177-phospho-eNOS and Thr495-phospho-eNOS was measured in cell extracts by flow cytometry using the BD Cytometric Bead Array Cell Signaling set. Ser473-phospho-Akt was quantified by Western blotting and by calculating the ratio Ser473-phospho-Akt/total Akt. Representative Western blots are shown. Values are expressed as the percent of values obtained in cells without incubation with HDL (basal). Data are means±SD (n=23 subjects in each group). Measurements were replicated 4× with HUVEC from 4 independent umbilical cords. total eNOS were measured by Western blotting for these S1P-loading experiments. The level of Ser1177-phospho-eNOS was significantly increased after S1P loading of HDL in comparison with the native MetS HDL (from 210±176% to 361±228%; P=0.038; Figure 3C ). The same tendency was observed for Akt-activating phosphorylation at Ser473, reaching the limit of significance (from 72±23% to 99±43%; P=0.050; Figure 3D ).
At the opposite, the S1P enrichment of HDL from control subjects by 27.6% did not induce any significant increase in eNOS activity or phosphorylation of eNOS at Ser1177 and Akt at Ser 473 (Figure 3 ).
TG Loading of Control HDL Does Not Mimic the Impairment of HDL-Induced eNOS Activation
Given the inverse correlation between the TG/apoA-I ratio in HDL fraction and HDL-induced eNOS activity and phosphorylation at Ser1177, we aimed to address the real involvement of TG enrichment of HDL in their impaired ability to activate eNOS in nondiabetic MetS patients. For this purpose, HDL from control subjects were loaded with TG and then incubated with HUVEC in parallel with the corresponding native HDL. TG loading of HDL from control subjects led to a 2.7-fold increase in the TG/apoA-I ratio (from 0.096±0.009 to 0.260±0.017; P=0.048; Figure 4A ). The cholesteryl esters/ apoA-I mass ratio tended to decrease after TG enrichment without reaching the level of significance (from 0.58±0.08 to 0.48±0.04; P=0.11). The free cholesterol/apoA-I, phospholipids/apoA-I, and apoA-I/total proteins mass ratios were all similar before and after TG enrichment (P>0.05, data not shown). In addition, the S1P/apoA-I ratio was not modified after TG enrichment (from 341±22 to 349±24 nmol/g apoA-I; P=0.77), nor was the apoM/apoA-I ratio (from 3.08±0.32% Figure 3 . Sphingosine-1-phosphate (S1P) loading of high-density lipoprotein (HDL) from nondiabetic metabolic syndrome (MetS) patients (A) restores their ability to stimulate endothelial nitric oxide synthase (eNOS) activity (B), promotes eNOS-activating phosphorylation at Ser1177 (C), and Akt (protein kinase B)-activating phosphorylation at Ser473 (D). HDL from 3 nondiabetic MetS patients and from 3 control subjects were enriched with S1P by incubation for 1 hour at room temperature with external S1P (A). Human umbilical vein endothelial cells (HUVEC) were incubated with dialyzed native (gray bars) and S1P-loaded HDL (black bars). The amount of Ser1177-phospho-eNOS and Ser473-phospho-Akt in cell extracts was measured by Western blotting and quantified by calculating Ser1177-phospho-eNOS/ total eNOS and Ser473-phospho-Akt/total Akt ratios, respectively. Representative Western blots are shown. Values are expressed as the percent of basal values obtained in cells without incubation with HDL. Data are means±SD (n=3 for each condition and each group). Measurements were replicated 3× for eNOS activity or 4× for phosphoproteins with HUVEC from independent umbilical cords. to 2.89±0.77%; P=0.73). TG-loaded HDLs were no less able than the corresponding native HDL to stimulate eNOS activity (86±33% versus 84±42%; P=0.90) and eNOS phosphorylation at Ser1177 (65±7% versus 73±21%; P=0.87) in HUVEC ( Figures 4B and 4C ).
Discussion
The major finding of this work was that the ability of HDL to activate eNOS was decreased in patients with MetS but without diabetes mellitus, and this defect is mainly explained by the decrease in S1P in HDL from these patients.
The lesser HDL-induced NO synthesis was related to a 1.4-fold decrease in the activation of eNOS by phosphorylation on Ser1177 with HDL from MetS patients, whereas the inhibiting phosphorylation of Thr495 was similar to that observed with HDL from controls. The phosphorylation of Ser1177 on eNOS is under the control of Akt, and we also observed a 1.4-fold decrease in the activating phosphorylation of Akt Ser473 by HDL from MetS patients.
Two potential explanations for the reduced activation of the Akt/eNOS signaling pathways were the TG enrichment and the lower S1P content in HDL from MetS patients. TG enrichment of HDL is a typical feature in MetS patients. 4, 5, 19 It is a consequence of hypertriglyceridemia, which accelerates heteroexchanges of TG and cholesteryl esters between very low-density lipoprotein and HDL, leading to an increased TG/ cholesteryl esters ratio in HDL. These modifications have been demonstrated to impair some functions of HDL. The replacement of cholesteryl esters by TG molecules in HDL reduces the exposure of apoA-I to the aqueous phase and impairs the antioxidant activity of HDL. 14, 15 Thus, the increase in TG content in HDL from patients with MetS may impair the binding of HDL to cell surfaces and decrease the activation of eNOS. This hypothesis was reinforced by our findings, which showed a significant inverse correlation between the TG/apoA-I ratio in HDL and their ability to activate eNOS in HUVEC. For better understanding of the pathophysiological impact of TG enrichment of HDL on eNOS activation, we loaded HDL from control subjects with TG and then evaluated their ability to stimulate eNOS in HUVEC. In fact, TG loading of HDL induced no decrease in eNOS activity and eNOS-activating phosphorylation at Ser1177. Therefore, TG enrichment of HDL does not seem to be decisive in explaining the impaired ability of HDL to stimulate eNOS in nondiabetic MetS patients. Our results can be considered together with those of Greene et al, 20 who demonstrated that in vitro TG enrichment of HDL did not change the amount of total neutral lipids taken up by scavenger receptor class B type I, suggesting that the affinity to scavenger receptor class B type I is unaltered.
On the other hand, by using a highly specific analysis by liquid chromatography coupled with tandem mass spectrometry, the present work demonstrated a decrease in the S1P content of HDL from patients with MetS compared with controls. This result is in accordance with another recent publication by our team. 6 The molecular basis for this HDL-S1P depletion in nondiabetic MetS patients remains unclear to date. Because apoM acts as a carrier for S1P in HDL, a decreased apoM content in HDL may cause S1P depletion in HDL. 21 This is all the more relevant because recent studies showed that only apoMcontaining HDL is responsible for the S1P-mediated protective effects of HDL. 17, 22 However, we did not find any alterations in HDL-apoM levels in MetS patients. Sattler et al 23 reported a similar pattern of normal amounts of apoM in S1P-depleted HDL in patients with coronary artery disease. Another explanation for the S1P depletion in HDL could be a switch of HDL size toward large HDL2 particles because HDL2 are less rich than HDL3 in S1P. 24 However, this mechanism is unlikely to occur in MetS patients because, on the contrary, the HDL size tends to decrease in these patients with a smaller HDL2/HDL3 ratio. [25] [26] [27] In addition, our group previously reported a decreased plasma S1P concentration in nondiabetic MetS patients in both the HDL (both HDL2 and HDL3) and non-HDL fractions, suggesting that the decrease in S1P in HDL is probably the consequence of a global decrease in plasma levels. 6 Because the binding of S1P to S1P receptors on endothelial cells triggers stimulation of the Akt/eNOS signaling pathway, we hypothesized that the S1P depletion of HDL could play an important role in the impaired eNOS activation in MetS. Thus, we enriched HDL from MetS patients with S1P and observed that S1P enrichment induced an increase in eNOS activity and eNOS-activating phosphorylation at Ser1177. Interestingly, eNOS activity was similar to that induced by HDL from control subjects with an S1P/apoA-I ratio comparable to that obtained in S1P-enriched HDL from patients with MetS. Taken together, these data emphasize that S1P depletion is the main factor responsible for the loss of HDL ability to stimulate eNOS in nondiabetic MetS patients. Interestingly, S1P enrichment of HDL from controls did not induce any significant increase in eNOS activation, suggesting that S1P concentration is optimal in healthy subjects and becomes a limiting factor only in patients exhibiting a decrease in its concentration.
HDL has been reported to be dysfunctional in MetS for some of their antiatherogenic properties, such as cholesterol efflux, antioxidative properties, and ability to counteract the deleterious effect of oxidative stress on vasorelaxation. 4, 5, 28 The present work adds further insights into the loss of the vascular protective effect of HDL in MetS at an early stage of the syndrome, before the appearance of hyperglycemia. The decreased activation of eNOS by HDL is likely to contribute to the loss of its ability to counteract the inhibitory effect of oxidized LDL on vasorelaxation we previously demonstrated. Consequently, it is likely to contribute to the increased cardiovascular risk associated with MetS. [1] [2] [3] Our results clearly underline the primordial role of S1P in HDL-induced vascular protection and the deleterious consequences of a moderate decrease in S1P content in HDL. They add further insights into the mechanisms likely to explain the inverse association between HDL S1P content and the occurrence and severity of coronary artery disease. 29, 30 Our data are in accordance with those obtained in type 2 diabetes mellitus on HDL-induced cardiac cell protection. 31 The activation of eNOS was also demonstrated after the S1P enrichment of HDL from patients with coronary artery disease but the final concentration of S1P in enriched HDL was 4 to 20 times higher than that in native HDL, which is not physiological. 23 Interestingly, we observed the normalization of eNOS activation with physiological S1P enrichment of HDL because the concentration of S1P in HDL obtained after the enrichment of HDL from MetS patients was the same as that in HDL from control subjects.
Some groups reported a decrease in paraoxonase activity in MetS or obese patients, 32, 33 whereas other teams did not. 4, 5, 15 Inhibition of paraoxonase activity in HDL leads to an increase in the malondialdehyde content of HDL. 34 Then, HDL-bound malondialdehyde can bind to lectin-like oxidized low-density lipoprotein receptor 1 on endothelial cells, which triggers a PKCβII-dependent eNOS phosphorylation at Thr495 and, subsequently, the inhibition of eNOS. As we observed no increase in HDL-induced eNOS phosphorylation at Thr495 in MetS patients compared with control subjects, we thought that the measurement of paraoxonase and malondialdehyde was not relevant to explain the decrease in eNOS activation.
In summary, the present study provides evidence that the ability of HDL to activate eNOS is impaired in MetS patients before the appearance of diabetes mellitus. This impairment diminishes the protective properties of these particles against atherosclerosis. S1P depletion of HDL is the main factor responsible for this deficiency because the in vitro normalization of HDL S1P content normalizes HDL-induced eNOS activation. These results encourage the development of therapeutic interventions to increase the S1P content of HDL, which will be relevant in MetS patients.
